Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. FDA Approves Roche/Chugai's Actemra For Second-line RA

This article was originally published in PharmAsia News

Executive Summary

Roche Japanese subsidiary Chugai's novel interleukin-6 inhibitor Actemra gained U.S. FDA approval Jan. 8 for treating patients with moderately to severely active rheumatoid arthritis for whom TNF blockers aren't working - a good beginning but still a ways from the first-line indication the pharma sought and still hopes to gain using data from its risk management programs and other sources

You may also be interested in...



Chugai Sets Record Results In 2009, Lowers Forecasts For 2010

Roche Japanese unit Chugai Pharmaceutical had its best year ever in 2009, posting record revenue and profits thanks largely to Tamiflu (oseltamivir), which saw Japan sales soar nine-fold to ¥76.2 billion ($852.75 million) in response to the Japanese government and local authorities stockpiling flu drugs

Chugai Sets Record Results In 2009, Lowers Forecasts For 2010

Roche Japanese unit Chugai Pharmaceutical had its best year ever in 2009, posting record revenue and profits thanks largely to Tamiflu (oseltamivir), which saw Japan sales soar nine-fold to ¥76.2 billion ($852.75 million) in response to the Japanese government and local authorities stockpiling flu drugs

Japan Approves Eisai's Humira, Mitsubishi Tanabe's Remicade In Same-day Approval For Psoriasis

TOKYO - Tokyo-headquartered Eisai and Osaka-based Mitsubishi Tanabe Pharma Jan. 20 simultaneously received Ministry of Health, Labor and Welfare approval to launch Japan's first fully human biological agents for the additional indication of psoriasis

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC072987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel